# Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

> **NCT04982939** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 210 (estimated)

## Conditions studied

- Gastric Cancer
- Perioperative
- Sintilimab

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** S-1
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT04982939
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-21
- **Primary completion:** 2023-06-21
- **Final completion:** 2024-06-21
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2021-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982939, "Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT04982939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*